CRISPR Editing in Suspension Cells: Techniques and Troubleshooting
CRISPR-Cas9 technology has revolutionized gene editing by providing precise, efficient tools to modify the genome. However, applying CRISPR to suspension cells such as leukemia and lymphoma lines remains technically challenging. These cells’ non-adherent nature and sensitivity to physical and chemical manipulation require specialized protocols to achieve effective gene editing without compromising cell viability.
The most common delivery method for CRISPR components in suspension cells is electroporation, which transiently permeabilizes the membrane, allowing direct entry of Cas9 protein, guide RNA, or plasmid DNA. Optimization of electroporation parameters—such as voltage, pulse duration, and buffer composition—is essential to balance editing efficiency and survival. Using ribonucleoprotein complexes (preassembled Cas9 protein with guide RNA) reduces off-target effects and improves editing speed.
Common troubleshooting steps include verifying cell viability before and after electroporation, ensuring high-quality nucleic acid preparations, and confirming guide RNA efficiency in silico. Post-editing, researchers must carefully select clones or enrich edited populations using fluorescence-activated cell sorting (FACS) or antibiotic selection.
Successful CRISPR editing in blood cancer models enables functional studies of oncogenes, tumor suppressors, and drug resistance genes, advancing targeted therapy development.
References: Altogen.com Altogenlabs.com